Pfizer Secures $1.5B Blackstone Funding to Accelerate Obesity Drug Pipeline

By / / Breaking News

This update was written automatically with AI from market data and news wire reports, and published without review by a person.

Key Takeaways

  • Pfizer (PFE) will receive up to $1.5 billion from Blackstone (BX) Life Sciences to fund the development of its obesity pipeline through 2028.
  • The funding specifically targets berobenatide, a potential first-in-class monthly GLP-1 receptor agonist peptide for chronic weight management.
  • Blackstone will receive milestone-based payments tied to U.S. regulatory approval and commercial sales, while Pfizer retains full ownership and control.
  • Pfizer plans to advance over 20 trials in the obesity space during 2026, including 10 Phase 3 trials for berobenatide.

Pfizer (PFE) and Blackstone (BX) Life Sciences announced a strategic co-funding agreement on Wednesday, under which Blackstone will provide up to $1.5 billion to support Pfizer’s obesity drug development. The capital injection is slated to cover development costs through 2028, specifically focusing on the advancement of berobenatide. This investigational drug is a monthly injectable GLP-1 receptor agonist that Pfizer acquired through its recent acquisition of Metsera.

The deal is structured as a risk-sharing partnership where Blackstone’s return is contingent on the drug's success. In exchange for the funding, Blackstone is eligible to receive milestone-based payments and royalties following U.S. regulatory approval and the achievement of specific commercial sales targets. This arrangement allows Pfizer to offload significant R&D costs while maintaining full operational control and 100% ownership of the asset.

Pfizer is aggressively positioning itself to compete with industry leaders Eli Lilly (LLY) and Novo Nordisk (NVO) in the lucrative weight-loss market. The company intends to launch more than 20 clinical trials related to obesity and its comorbidities in 2026. Berobenatide is currently the "anchor" of this cardiometabolic pipeline, with 10 Phase 3 trials either ongoing or planned to study the drug for weight management, knee osteoarthritis, and sleep apnea.

The partnership comes at a critical time for Pfizer as it seeks to offset declining revenue from its COVID-19 portfolio. By leveraging Blackstone's capital, Pfizer's Chief Financial Officer Cecile Guegan noted that the company can maintain the "financial capacity and flexibility" to invest in its broader pipeline across other therapeutic areas like oncology. Market analysts view this as a disciplined move to accelerate a high-potential program without further straining the company's internal balance sheet.

Blackstone Life Sciences, which currently manages approximately $18 billion in assets, will utilize funds from its perpetual private equity strategy (BXPE) for this investment. This deal marks one of the largest private funding commitments for a single drug program in recent years, highlighting the high conviction in the GLP-1 market, which some analysts project could exceed $100 billion by the end of the decade.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top